In this episode of Unsupervised Learning, Jacob interviews Joshua Meier, CEO of Chai Discovery, about the application of AI in biology and drug discovery. They discuss the evolution of AI in drug discovery over the last decade, from early deep learning models to the current wave of bio-foundation model companies. Meier explains how AI is being used in clinical trials, target discovery, and drug design, highlighting Chai Discovery's work in designing molecules with high success rates. They explore the role of data generation, open-source models, and the potential for AI to revolutionize the pharmaceutical industry by enabling the creation of better and previously impossible-to-discover drugs. The conversation touches on the future of pharma, the importance of focusing on solving real-world problems, and the milestones to watch for in the AI bio space.
Sign in to continue reading, translating and more.
Continue